British CDMO Sterling partners up on low-cost manufacturing of molnupiravir
A British CDMO and the University of Manchester have teamed up to support the development of low-cost manufacturing of molnupiravir, the antiviral pill for Covid-19 that an FDA adcomm recommended for an EUA earlier this week.
Manchester’s Institute of Biotechnology enlisted Sterling to provide chemical scale-up and process development expertise. That could potentially provide broader access of molnupiravir to lower-income countries. The school has received grant funding from the Bill & Melinda Gates Foundation for the project.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.